In pregnancies achieved through programmed frozen embryo transfer cycle (PC-FET) and modified natural frozen embryo transfer (mNC-FET), to determine whether there are differences in endothelial and placental function, maternal cardiovascular function, fetal growth and fetal cardiovascular and cerebral programming and to assess whether there is an association between these differences and the plasma concentrations of the main secretion products of the Corpus Luteum (CL) with vasoactive and angiogenic action.
Female patients 18- 37 years old (both included) at the time of oocyte retrieval and less than 41 years of age at the time of embryo transfer.
Regular menstrual cycles between 24 and 35 days.
Availability of cryopreserved blastocysts from own gametes
Indication for single embryo transfer.
Recurrent pregnancy loss (3 or more).
Recurrent implantation failure in previous IVF treatments (3 or more unsuccessful embryo transfers). .
Diagnosis of polycystic ovarian syndrome, diabetes mellitus, chronic arterial hypertension, maternal heart disease and autoimmune diseases (Systemic Lupus Erythematosus (SLE) or Antiphospholipid syndrome (APS)).
Active treatment with aspirin, heparin or other anticoagulant therapy, antihypertensives or other drugs used to treat circulation or coagulation disorders .
Parallel
Estradiol + Progesterone
DrugPregnancies with absence of corpus luteum(PC-FET)
Ovitrelle ( Hcg 250 mcg)
DrugNC-FET(natural cycle FET, endometrial preparation with presence of CL)
Maternal: Relaxin-2 plasma concentrations.
Fetal: Mitral annular plane systolic excursion (MAPSE) assessed by echocardiography.
Angiogenic/vasoactive function of corpus luteum and placenta
plasma concentrations of VCAM-1 and endoglin.
Maternal endothelial function
Maternal echocardiography: cardiac output (L/min)
Click on the lead sponsor to view all of their trials.
